Vendor Intelligence Report: Royal Peptides

Published 13 Jun 2026. 25-page investigative report on who is behind Royal Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Royal Peptides posts 22 pass / 9 fail across 31 Finnrick lab tests, a 71% overall pass rate; Tirzepatide and Semaglutide look more defensible than Retatrutide, which carries a severe 40mg short-fill…